Meltpeak
Food supplement declared in France, decision dated 27 October 2026
Meltpeak (Meltpeak) is a food supplement declared in France. Status: declared in France, may be marketed. 2 rules of use apply to its ingredients (limits and warnings).
- Brand
- Meltpeak
- Food business operator placing the product on the market
- Bralex Webshops B.V.
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 2
- Directions for use
- Instructions : Prenez deux gélules par jour. Prenez 1 gélule 30 minutes avant le petit-déjeuner et 1 gélule 30 minutes avant le dîner. Avalez les géluues avec de l’eau.. Conservation : Tenir hors de portée des enfants. Conserver dans un endroit frais et sec, à température ambiante (inférieure à 30 degrés Celsius).
- Intended populations
- Men and women aged 18 and over
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Kidney stones, Taking away from meals, Pregnant women, Kidney failure, Kidney disease, Heart problems, Taking thyroid medication, Ulcer (stomach or duodenum)
- Objectives stated by the manufacturer (these are not authorised claims)
- Weight management / Slimming
Declaration 380475, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Rubus idaeus L. | Fruit | Poudre (de plantes séchées ou broyées) | 200 mg |
| Paullinia cupana Kunth | Graine | Autre extrait sec | 200 mg |
| Camellia sinensis (L.) Kuntze | Feuille | Autre extrait sec | 200 mg |
| Coffea arabica L. | Graine | Autre extrait sec | 160 mg |
Substances
| Name | Per day |
|---|---|
| caféine | 145 mg |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-biotine | Biotine (vitamine B8) | pas de limite (données insuffisantes) | dose annulled by the French Council of State in 2011 |
| Picolinate de chrome | Chrome | pas de limite (données insuffisantes) | 25 µg |
| Oxyde de zinc | Zinc | 25 mg | 15 mg |
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Avertissement : Contient de la caféine (148,5 mg par dose journalière). Ne pas utiliser pendant la grossesse (ou en cas de désir de grossesse) ou l’allaitement. Ne convient pas aux enfants de moins de 18 ans. Ne pas utiliser en cas de problèmes rénaux. Ce produit est un complément alimentaire. Ne pas dépasser la dose journalière recommandée. Une alimentation variée et équilibrée ainsi qu’un mode de vie sain sont importants. Un complément alimentaire ne peut pas s’y substituer. Consultez un médecin en cas de prise de médicaments ou de suivi médical. Ne pas associer avec des médicaments cardiovasculaires. Laissez un intervalle de 1 à 2 heures entre la prise de médicaments et celle du thé vert. La dose journalière maximale d’EGCG (gallate d’épigallocatéchine-3) est de 800 mg. Ne pas consommer à jeun. Ne pas associer avec d’autres produits à base de thé vert.
Regulatory points
- Conditions légales
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
Source: Regulation (EC) No 1925/2006, latest consolidated version, annexe III, partie B (règlement (UE) 2022/2340).
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Coffea arabica L.
Read the warning, when it applies and the studies cited
GREEN COFFEE BEAN EXTRACT
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Contraindications
Do not use if you are pregnant.
- caféine
Read the warning, when it applies and the studies cited
CAFFEINE
Route of administration: Oral (Higdon and Frei 2006)
Cautions and warnings
Applies to products providing 100 mg to 400 mg caffeine, per day1.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).
Sources cited by Health Canada (7)
- Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
- Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Randomised trial
- Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
- Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Review article
- Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Clinical trial
- Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Meta-analysis
- Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Meta-analysis
1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.
Applies to products providing more than 300 mg caffeine, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant, breastfeeding, or attempting to conceive (Nawrot et al. 2003).
Sources cited by Health Canada (1)
- Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Additives and Contaminants 2003;20(1):1-30. PubMed Review article
Applies to products providing 400 mg or more caffeine, per day.
When using this product avoid taking other health products, foods or beverages that contain caffeine and/or increase blood pressure (FDA 2023; Bui et al. 2006; Bouchard et al. 2005; Haller et al. 2005; NIH 2004; Berardi et al. 2002; Vahedi et al. 2000; Zimmerman 1992).
Sources cited by Health Canada (8)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Bouchard NC, Howland MA, Greller HA, Hoffman RS, Nelson LS. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clinic Proceeding 2005;80(4):541-545. PubMed Case report
- Bui LT, Nguyen DT, Ambrose PJ. Blood pressure and heart rate effects following a single dose of bitter orange. The Annals of Pharmacotherapy 2006;40(1):53-57. PubMed Randomised trial
- FDA 2023: Food and Drug Administration. Title 21 Chapter 1 Part 340. Stimulant drug products for over-the-counter human use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services; 2023. [Accessed 2023 Aug 28]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=340&showFR=1
- Haller CA, Benowitz NL, Jacob P. Hemodynamic effects of ephedra-free weight-loss supplements in humans. The American Journal of Medicine 2005;118(9):998-1003. PubMed Randomised trial
- NIH 2004: National Institutes of Health. Office of Dietary Supplements. Fact sheets. Ephedra and ephedrine alkaloids for weight loss and athletic performance; 2004. [Accessed 2023 August 28]. Available from: https://ods.od.nih.gov/factsheets/ephedraandephedrine-HealthProfessional/.
- Vahedi K, Domingo V, Amarenco P, Bousser MG. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. Journal of Neurology, Neurosurgery and Psychiatry 2000;68(1):112-113. PubMed Case report
- Zimmerman DR. Zimmerman's Complete Guide to Nonprescription Drugs, 2nd edition. Detroit (MI): Gale Research Inc.; 1992.
Contraindications
Applies to products providing more than 400 mg caffeine per day.
Do not use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).
Sources cited by Health Canada (7)
- Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
- Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Randomised trial
- Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
- Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Review article
- Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Clinical trial
- Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Meta-analysis
- Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Meta-analysis
Known adverse reactions
Condition of application: All products.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if hypersensitivity/allergy occurs (Infante et al. 2003; Hinrichs et al. 2002).
Sources cited by Health Canada (2)
Applies to products providing 200 mg or more caffeine, per day.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms such as chest pain and irregular heartbeat occur (Higgins and Babu 2013).
Sources cited by Health Canada (1)
- Higgins JP, Babu KM, Caffeine reduces myocardial blood flow during exercise. The American Journal of Medicine 2013;126(8):730-e 1-8.
Applies to products providing more than 400 mg caffeine, per day.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if nervousness, anxiety, insomnia, tremor and/or headache occur (IOM 2001, Zhang 2001, Sawynok 1995).
Sources cited by Health Canada (3)
- IOM 2001: Institute of Medicine. Committee on Military Nutrition Research, Food and Nutrition Board, Institute of Medicine. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington (DC): National Academy Press; 2001 [Accessed 2023 Aug 28]. Available from: http://books.nap.edu/openbook.php?isbn=0309082587.
- Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995;49(1):37-50. PubMed Review article
- Zhang WY. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Safety 2001;24(15):1127-1142. PubMed Review article
Condition of application: All products except those making a diuretic claim1.
When using this product diuretic effect may occur.
1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : Meltpeak
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.